Fig. 2. BRAF mutated melanoma responds to BRAF/MEK inhibitors-targeted therapy; Development of BRAF/MEK inhibitors-targeted therapy resistance. RTK: receptor tyrosine kinases; MITF: Melanocyte Inducing Transcription Factor; POU4F1: POU Domain, Class 4, Transcription Factor 1.